{"id":31447,"date":"2025-04-09T15:53:52","date_gmt":"2025-04-09T07:53:52","guid":{"rendered":"https:\/\/flcube.com\/?p=31447"},"modified":"2025-04-09T15:53:53","modified_gmt":"2025-04-09T07:53:53","slug":"bio-thera-solutions-reports-5-44-revenue-growth-in-2024-driven-by-biosimilar-sales","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31447","title":{"rendered":"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales"},"content":{"rendered":"\n

Guangzhou-based Bio-Thera Solutions (SHA: 688177<\/a>) announced its 2024 financial results, recording RMB 743.17 million (USD 101.41 million) in revenues, reflecting a 5.44% year-on-year (YOY) increase. This growth is attributed to steady sales of its biosimilar products, Qletli (adalimumab) and Shiruili (tocilizumab), alongside the initiation of overseas supply operations for Shiruili.<\/p>\n\n\n\n

Product Portfolio<\/strong>
Bio-Thera has four products approved in China: Qletli, Avzivi (bevacizumab biosimilar), Shiruili, and Betagrin (batifiban). Two products, Tofidence (tocilizumab biosimilar) and Avzivi, are approved in the US and European Union (EU), while Bevyx (bevacizumab biosimilar) is approved in Brazil.<\/p>\n\n\n\n

Regulatory Progress<\/strong>
The company is awaiting regulatory decisions for BAT2206 (ustekinumab biosimilar) in China, the US, and EU; BAT2506 (golimumab biosimilar) in the EU and China; and BAT2306 (secukinumab biosimilar) in China. Additionally, BAT4406F, BAT3306, BAT1308, BAT8006, and BAT5906 are in Phase III or pivotal regulatory clinical trials.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD…<\/p>\n","protected":false},"author":1,"featured_media":31448,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[289,27,1055],"class_list":["post-31447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-bio-thera-solutions","tag-finanical-reports","tag-sha-688177"],"yoast_head":"\nBio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD 101.41 million) in revenues, reflecting a 5.44% year-on-year (YOY) increase. This growth is attributed to steady sales of its biosimilar products, Qletli (adalimumab) and Shiruili (tocilizumab), alongside the initiation of overseas supply operations for Shiruili.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31447\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales\" \/>\n<meta property=\"og:description\" content=\"Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD 101.41 million) in revenues, reflecting a 5.44% year-on-year (YOY) increase. This growth is attributed to steady sales of its biosimilar products, Qletli (adalimumab) and Shiruili (tocilizumab), alongside the initiation of overseas supply operations for Shiruili.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31447\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T07:53:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-09T07:53:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0906-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales\",\"datePublished\":\"2025-04-09T07:53:52+00:00\",\"dateModified\":\"2025-04-09T07:53:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447\"},\"wordCount\":149,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0906-png.webp\",\"keywords\":[\"Bio-Thera Solutions\",\"Finanical Reports\",\"SHA: 688177\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31447#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31447\",\"name\":\"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0906-png.webp\",\"datePublished\":\"2025-04-09T07:53:52+00:00\",\"dateModified\":\"2025-04-09T07:53:53+00:00\",\"description\":\"Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD 101.41 million) in revenues, reflecting a 5.44% year-on-year (YOY) increase. This growth is attributed to steady sales of its biosimilar products, Qletli (adalimumab) and Shiruili (tocilizumab), alongside the initiation of overseas supply operations for Shiruili.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31447\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0906-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0906-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31447#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales - Insight, China's Pharmaceutical Industry","description":"Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD 101.41 million) in revenues, reflecting a 5.44% year-on-year (YOY) increase. This growth is attributed to steady sales of its biosimilar products, Qletli (adalimumab) and Shiruili (tocilizumab), alongside the initiation of overseas supply operations for Shiruili.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31447","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales","og_description":"Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD 101.41 million) in revenues, reflecting a 5.44% year-on-year (YOY) increase. This growth is attributed to steady sales of its biosimilar products, Qletli (adalimumab) and Shiruili (tocilizumab), alongside the initiation of overseas supply operations for Shiruili.","og_url":"https:\/\/flcube.com\/?p=31447","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-09T07:53:52+00:00","article_modified_time":"2025-04-09T07:53:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0906-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31447#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31447"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales","datePublished":"2025-04-09T07:53:52+00:00","dateModified":"2025-04-09T07:53:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31447"},"wordCount":149,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31447#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0906-png.webp","keywords":["Bio-Thera Solutions","Finanical Reports","SHA: 688177"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31447#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31447","url":"https:\/\/flcube.com\/?p=31447","name":"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31447#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31447#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0906-png.webp","datePublished":"2025-04-09T07:53:52+00:00","dateModified":"2025-04-09T07:53:53+00:00","description":"Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD 101.41 million) in revenues, reflecting a 5.44% year-on-year (YOY) increase. This growth is attributed to steady sales of its biosimilar products, Qletli (adalimumab) and Shiruili (tocilizumab), alongside the initiation of overseas supply operations for Shiruili.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31447#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31447"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31447#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0906-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0906-png.webp","width":1080,"height":608,"caption":"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31447#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0906-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31447"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31447\/revisions"}],"predecessor-version":[{"id":31449,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31447\/revisions\/31449"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31448"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}